Azar Baradaran
* 
1 Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
Implication for health policy/practice/research/medical education
Sclerostin is a glycoprotein with 190-amino-acid, which is mainly released by osteocytes. Sclerostin reduces bone construction following preventing the final differentiation of osteoblasts and accelerating their apoptosis. The exact role of sclerostin in dialysis patients requires further studies since some authors believe that this biomarker has a relationship with bone-vascular axis and accordingly with parathyroid function. It is possible that, sclerostin related to the all-cause mortality, coronary artery calcifications and the prevalence of heart and vascular events.
Please cite this paper as: Baradaran A. Sclerostin in hemodialysis patients. J Parathyr Dis. 2020;8:e11177.